Injective price dips amid rising selling pressure

Traders Union
All News
Crypto News
Injective slides 10.32% today to $5

Highlights

Injective introduced onchain pre-IPO markets for private companies and a token buyback program, advancing its role in decentralized finance.
Ecosystem activity increased with early USDC integration and broader positioning toward real-world asset tokenization, though price action remains under broader selling pressure.
Technical signals show overbought conditions as INJ/USD consolidates between $4.59 and $5.62, with increased downside risk dominating short-term prospects.

Ecosystem growth and supply reduction initiatives counter broader selling pressure

Injective recently launched onchain pre-IPO markets, enabling trading of price exposure for private companies such as OpenAI, SpaceX, and Anthropic. The platform also initiated a Community BuyBack program to reduce INJ token supply through buybacks and burns, and began progress on USDC integration via CCTP, which contributed to higher trading volume and ecosystem activity. The Injective ecosystem was further highlighted as positioning itself for real-world assets and decentralized finance applications, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes that Injective’s price action is under clear selling pressure despite a superficially bullish technical alignment. He points to the sharp 10.32% daily drop and a downside gap, suggesting bulls have lost momentum in the near term. Overbought signals across multiple oscillators cast doubt on the sustainability of recent gains. The analyst identifies risks in the disconnect between positive news flows and weak market response. "A further breakdown toward $4.59 support cannot be ruled out if buyers fail to reclaim higher ground soon," Kharitonov warns.

Viktoras Karapetjanc, expert at Traders Union, sees Injective maintaining a strong structural advantage above all key moving averages. He highlights recent ecosystem growth, especially the launch of pre-IPO markets and new buyback initiatives, as drivers for sustained adoption and confidence. Karapetjanc believes the bullish structure remains intact, with short-term consolidations offering strategic opportunities. "As the market recognizes Injective’s innovation and supply reduction, I expect further growth beyond the current range," he says.

Overbought signals build as bullish trend collides with corrective momentum

INJ/USD is currently trading above the 20-day ($3.92), 50-day ($3.38), and 200-day ($4.44) Simple Moving Averages, affirming a bullish short-, medium-, and longer-term structure. The next important dynamic support is the Kijun line from the Ichimoku indicator at $4.62, with resistance emerging near the recent daily high or round levels just above $5.50.

Momentum readings are mixed. The MACD on the daily timeframe signals continued upside, supported by a strong daily ADX, although overbought readings appear on the Relative Strength Index (RSI), Stochastic RSI, and Commodity Channel Index (CCI). Bull/Bear Power (BBP) above zero indicates buyers remain in control, though it is also flagged as overbought. The Awesome Oscillator remains positive, aligning with the short-term trend. The pair dropped 10.32% on the session, opening with a downside gap of about $0.42. Price action is near the lower end of today’s range, and intraday volatility stands at 8.35%. Overall, there is visible pressure after the open. Overbought conditions diverge from the corrective price action, hinting at potential for further downside or consolidation in the near term.

Earlier, analysts noted that Injective's strong technical structure was tempered by overbought risks and the possibility of a short-term pullback. With recent volatility and mixed momentum readings despite ongoing ecosystem developments, traders should watch for a potential shift toward further downside or consolidation if price fails to reclaim resistance above $5.62.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.